Alamandine

金刚烷

Alamandine

A649067-5mg

5mg

≥98%

干燥,-80℃储存

超低温冰袋运输

Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions. In Vitro Alamandine is generated by catalysis of Ang A via ACE2 or directly from Angiotensin 1-7 (Ang-(1-7)). Derived from angiotensin II (Ang II) by Ang II-converting enzyme 2 (ACE2), it shows vasodilating (thus protective) properties. Ang (1-7) can be decarboxylated to a peptide called Alamandine. Alamandine is also an endogenous peptide identified in human blood. Alamandine elevates cAMP concentration in primary endothelial and mesangial cells, also suggesting Gs coupling. Alamandine decreases secretion, expression, and blood levels of leptin. Alamandine induced expression of iNOS and plasminogen activator inhibitor-1 (PAI-1) in adipose tissue and isolated adipocytes. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Alamandine (0.15 μL/h; administered by mini-osmotic pumps; for 6 weeks) treatment ameliorates hypertension and impaires left ventricle (LV) function in SHRs. Also decreases the mass gains of heart and lung in SHRs, suppresses cardiomyocyte cross-sectional area expansion, and inhibits the mRNA levels of atrial natriuretic peptide and brain natriuretic peptide. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male spontaneously hypertensive rats (SHRs, 50-week-old)Dosage: 0.15 μL/h (~50 μg/kg/day) Administration: Administered by mini-osmotic pumps; for 6 weeks Result: Attenuated hypertension, alleviated cardiac hypertrophy, and improved LV function. Form:Solid

阿拉曼定是肾素-血管紧张素系统（RAS）的成员，是一种血管活性肽，是 G 蛋白偶联受体 MrgD 的内源性配体。阿拉曼丁通过抗高血压作用保护肾脏和心脏。

1176306-10-7

C40H62N12O9

855 g/mol

44192273

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)N

(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid

1S/C40H62N12O9/c1-6-22(4)32(37(58)49-29(18-25-19-44-20-46-25)38(59)52-16-8-10-30(52)39(60)61)51-35(56)28(17-24-11-13-26(53)14-12-24)48-36(57)31(21(2)3)50-34(55)27(47-33(54)23(5)41)9-7-15-45-40(42)43/h11-14,19-23,27-32,53H,6-10,15-18,41H2,1-5H3,(H,44,46)(H,47,54)(H,48,57)(H,49,58)(H,50,55)(H,51,56)(H,60,61)(H4,42,43,45)/t22-,23-,27-,28-,29-,30-,31-,32-/m0/s1

QVMYBFKDLPBYSO-GIGALADGSA-N

CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)N

H2O : 25 mg/mL (29.24 mM; Need ultrasonic)

11

12

23

854.476 Da

854.476 Da

342.000 Ų

61

0

1540.000

0

1

-2.100

37058029